Targeting the Hippo pathway in common complex sarcomas
Project 2: Targeting the Hippo Pathway in Genetically Complex Sarcomas
Seeks to block a cancer growth system (the Hippo pathway and eIF4A) to help people with four aggressive, genetically complex sarcomas: well-differentiated and dedifferentiated liposarcoma, myxofibrosarcoma, and undifferentiated pleomorphic sarcoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11181588 on NIH RePORTER |
What this research studies
This project aims to find targeted drugs for four aggressive sarcoma types that often return after surgery. Researchers will study how the Hippo pathway and its effectors YAP and TAZ drive tumor growth and spread using tumor samples, cell lines, and animal models. They will test a new drug that inhibits the translation factor eIF4A (TDI-7663) to see if it reduces YAP/TAZ protein levels and tumor growth. Promising lab and animal results would support steps toward early human testing.
Who could benefit from this research
Good fit: People with well-differentiated liposarcoma, dedifferentiated liposarcoma, myxofibrosarcoma, or undifferentiated pleomorphic sarcoma—especially those with recurrent, advanced, or metastatic disease—are the most relevant candidates.
Not a fit: Patients with other cancer types, those already cured by local therapy, or whose tumors do not rely on Hippo signaling are less likely to benefit.
Why it matters
Potential benefit: Could produce new targeted treatments that slow or stop growth and spread of these sarcomas, offering options for patients with recurrent or advanced disease.
How similar studies have performed: Targeting YAP/TAZ and using eIF4A inhibitors is a relatively new approach with encouraging preclinical data but limited clinical proof to date.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Singer, Samuel — Sloan-Kettering Inst Can Research
- Study coordinator: Singer, Samuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.